MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Hemodialysis Complication, Hemodynamic Instability

In brief

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

Key facts

Study ID

NCT04428372

Run by

Brigham and Women's Hospital

People needed

31

Starts

2021-04-06

Expected to finish

2024-12-31

Last updated by the study team

2025-11-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Maintenance HD (>90 days)
• Age ≥18y
• Thrice-weekly HD
• IDH-prone (defined as nadir intra-dialytic SBP <100 mmHg in ≥30% of sessions in the prior 4 weeks)
• Hematocrit>21%
• Written informed consent

You may not qualify if…

• Acute myocardial infarction or stroke within one month
• Pre-HD serum potassium >6.5 mmol/L in last 4 weeks
• Pregnancy
• Institutionalized individuals
• Life expectancy <2 months
• Planned renal transplant within 2 months
• Active enrollment in another interventional trial
• Known allergy to mannitol

Where it is running

• Brigham and Women's — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.